BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	3.13	7.42	9.51	9.77	10.93	13.36
Revenue Growth	-67.27%	-21.93%	-2.66%	-10.60%	-18.21%	17.31%
Gross Profit Gross Profit Growth	0.39	1.09	1.29	1.33	1.26	2.27
Operating Income Operating Income Growth	-2.76	-3.1	-1.9	-3.04	-0.22	1.06
Net Income Net Income Growth	-2.58	-2.98	-1.6	-2.63	-0.36	0.75
Earnings Per Share EPS Growth	-1.19	-1.61	-0.90	-1.66	-0.25	0.53
EPS Growth	-	-	-	-	-	-58.71%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Trading of Industrial Chemicals Trading of Industrial Chemicals Growth	3.11	7.41	9.49	9.75	10.83	11.85
Provision for Genomic Screening Services Provision for Genomic Screening Services Growth	0.01	0.02	0.02	0.02	0.1	1.52
Total Total Growth	3.13	7.42	9.51	9.77	10.93	13.36

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	3.52	4.04	4.38	5.93	2.12	2.12
Total Debt Total Debt Growth	0.32	0.23	0.23	0.15	0.06	0.08
Net Cash (Debt) Net Cash Growth	3.2	3.81	4.15	5.78	2.06	2.05
Net Cash Growth	12.38%	-8.09%	-28.24%	180.43%	0.74%	-23.17%
Net Cash Per Share Net Cash Per Share Growth	1.48	2.05	2.33	3.64	1.43	1.43

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-0.85	-1.84	-2.09	-1.82	0.55	0.01
Capital Expenditures CapEx Growth	-0.01	-0.04	-0.23	-0.15	-0.05	-0
Free Cash Flow Free Cash Flow Growth	-0.85	-1.88	-2.32	-1.97	0.5	0.01
Free Cash Flow Growth	-	-	-	-	8195.57%	-95.42%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	12.34%	14.62%	13.56%	13.61%	11.52%	16.96%
Operating Margin	-88.16%	-41.74%	-19.95%	-31.09%	-2.02%	7.90%
Pretax Margin	-82.36%	-40.20%	-16.77%	-26.69%	-2.78%	7.80%
Profit Margin	-82.36%	-40.20%	-16.81%	-26.91%	-3.26%	5.62%
FCF Margin	-27.30%	-25.26%	-24.40%	-20.18%	4.55%	0.04%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 9, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	-	-	-	-	-	485.24
P/FCF Ratio	-	-	-	-	331.62	60792.56
PS Ratio	1.31	1.26	0.53	0.96	15.10	27.29

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 4, 2026

Data Sources Report a data error